<DOC>
	<DOCNO>NCT03047278</DOCNO>
	<brief_summary>This study aim investigate influence glycemic control type 2 diabetes ( DM2 ) cetirizine ( OCT2 inhibitor ) gabapentin kinetics disposition pharmacokinetics-pharmacodynamics ( PK-PD ) patient neuropathic pain . Thus , non-diabetic patient ( Control Group , n=10 ) , patient control diabetes ( n=10 ) patient uncontrolled diabetes ( n=10 ) , neuropathic pain intensity ≥ 4 pain visual analog scale ( 0-10 ) investigate .</brief_summary>
	<brief_title>Influence OCT2 Inhibitor Cetirizine Type 2 Diabetes Gabapentin Kinetics Disposition Patients With Neuropathic Pain</brief_title>
	<detailed_description>Organic cation transporter 2 ( OCT2 ) , express basolateral membrane kidney proximal tubule , promote elimination endogenous compound clinically use drug . Gabapentin ( GBP ) anticonvulsant use neuropathic pain treatment , eliminate primarily renal excretion , dependent OCT2 activity . Studies rat diabetes suggest hyperglycemia reduces OCT2 activity approximately 50 % . The aim study investigate influence glycemic control type 2 diabetes ( DM2 ) cetirizine ( OCT2 inhibitor ) gabapentin kinetics disposition pharmacokinetics-pharmacodynamics ( PK-PD ) patient neuropathic pain . Non-diabetic patient ( Control Group , n=10 ) , patient control diabetes ( n=10 ) patient uncontrolled diabetes ( n=10 ) , neuropathic pain intensity ≥ 4 pain visual analog scale ( 0-10 ) recruit include research protocol . Patients treated oral single dose GBP 300 mg ( Phase I ) cetirizine ( 20 mg/day ) 5 day single dose GBP last day ( Phase II ) . Only patient Control Group participate Phase II . Serial blood sample collect 36 hour GBP administration , urine collect 0-8 hour , 8-16 hour , 16-24 hour 24-36 hour interval . The intensity pain evaluate time blood sampling , use visual analog scale . GBP concentration plasma validate LC-MS , GBP concentration urine validate Liquid Chromatography-Mass Spectrometer ( LC-MS ) . Patients genotyped polimorphism 808 G &gt; T Solute Carrier 22A2 ( SLC22A2 ) gene . Pharmacokinetics parameter area curve ( AUC ) , total clearance , renal clearance , volume distribution elimination half-life estimate non-compartmental analysis . Based result , possible evaluate relevance OCT2 activity GBP pharmacokinetics , necessity dose adjustment GBP patient DM2 .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Neuralgia</mesh_term>
	<mesh_term>Diabetic Neuropathies</mesh_term>
	<mesh_term>Cetirizine</mesh_term>
	<mesh_term>Gabapentin</mesh_term>
	<mesh_term>gamma-Aminobutyric Acid</mesh_term>
	<criteria>Adult patient , gender Patients neuropathic pain score ≥ 4 visual analog scale Patients control type 2 diabetes ( glycated hemoglobin ≤ 7.0 % ) diabetic neuropathy score ≥ 4 visual analog scale Patients uncontrolled type 2 diabetes ( glycated hemoglobin ≥ 7.0 % ) diabetic neuropathy score ≥ 4 visual analog scale Patients suspend use analgesic 10 time halflife start protocol Patients acute chronicle renal failure ( creatinine clearance ≤ 50 mL/min ) Patients gastrointestinal disease Patients history alcohol drug abuse Patients acute myocardial insufficiency Patients morbid obesity ( BMI &gt; 40 kg/m² ) Patients another kind chronicle pain severe neuropathic pain Patients chronicle use drug interact gabapentin ( antacids cimetidine )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>59 Years</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>